مورد إلكتروني
A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer.
| العنوان: | A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer. |
|---|---|
| المؤلفون: | Blau, C Anthony |
| المصدر: | Journal of the National Comprehensive Cancer Network : JNCCN; vol 14, iss 1, 8-17; 1540-1405 |
| بيانات النشر: | eScholarship, University of California 2016-01-01 |
| تفاصيل مُضافة: | Blau, C Anthony Ramirez, Arturo B Blau, Sibel Pritchard, Colin C Dorschner, Michael O Schmechel, Stephen C Martins, Timothy J Mahen, Elisabeth M Burton, Kimberly A Komashko, Vitalina M Radenbaugh, Amie J Dougherty, Katy Thomas, Anju Miller, Christopher P Annis, James Fromm, Jonathan R Song, Chaozhong Chang, Elizabeth Howard, Kellie Austin, Sharon Schmidt, Rodney A Linenberger, Michael L Becker, Pamela S Senecal, Francis M Mecham, Brigham H Lee, Su-In Madan, Anup Ronen, Roy Dutkowski, Janusz Heimfeld, Shelly Wood, Brent L Stilwell, Jackie L Kaldjian, Eric P Haussler, David Zhu, Jingchun |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Accelerating cancer research is expected to require new types of clinical trials. This report describes the Intensive Trial of OMics in Cancer (ITOMIC) and a participant with triple-negative breast cancer metastatic to bone, who had markedly elevated circulating tumor cells (CTCs) that were monitored 48 times over 9 months. A total of 32 researchers from 14 institutions were engaged in the patient's evaluation; 20 researchers had no prior involvement in patient care and 18 were recruited specifically for this patient. Whole-exome sequencing of 3 bone marrow samples demonstrated a novel ROS1 variant that was estimated to be present in most or all tumor cells. After an initial response to cisplatin, a hypothesis of crizotinib sensitivity was disproven. Leukapheresis followed by partial CTC enrichment allowed for the development of a differential high-throughput drug screen and demonstrated sensitivity to investigational BH3-mimetic inhibitors of BCL-2 that could not be tested in the patient because requests to the pharmaceutical sponsors were denied. The number and size of CTC clusters correlated with clinical status and eventually death. Focusing the expertise of a distributed network of investigators on an intensively monitored patient with cancer can generate high-resolution views of the natural history of cancer and suggest new opportunities for therapy. Optimization requires access to investigational drugs. |
| مصطلحات الفهرس: | Humans, Bone Neoplasms, Neoplasm Metastasis, Antineoplastic Combined Chemotherapy Protocols, Leukapheresis, Drug Screening Assays, Antitumor, Longitudinal Studies, Follow-Up Studies, Drug Resistance, Neoplasm, Expert Testimony, Community Networks, Middle Aged, Research Personnel, Female, Neoplastic Cells, Circulating, Triple Negative Breast Neoplasms, Breast Cancer, Clinical Research, Biotechnology, Clinical Trials and Supportive Activities, Cancer, Good Health and Well Being, Oncology & Carcinogenesis, article |
| URL: | |
| الإتاحة: | Open access content. Open access content public |
| ملاحظة: | application/pdf Journal of the National Comprehensive Cancer Network : JNCCN vol 14, iss 1, 8-17 1540-1405 |
| أرقام أخرى: | CDLER oai:escholarship.org:ark:/13030/qt3236q55n qt3236q55n https://escholarship.org/uc/item/3236q55nTest https://escholarship.orgTest/ 1378689559 |
| المصدر المساهم: | UC MASS DIGITIZATION From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1378689559 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |